X4 Pharmaceuticals, Inc. (XFOR) News
Filter XFOR News Items
XFOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XFOR News Highlights
- For XFOR, its 30 day story count is now at 2.
- Over the past 6 days, the trend for XFOR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ASH, DEC and RARE are the most mentioned tickers in articles about XFOR.
Latest XFOR News From Around the Web
Below are the latest news stories about X4 PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XFOR as an investment opportunity.
XFOR: Update on Phase 2 CN Trial at ASH 2023By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Case Studies of First Three Patients from Phase 2 CN Trial Presented at ASH 2023 On December 9, 2023, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced that additional preliminary data from the company’s ongoing Phase 2 clinical trial of mavorixafor in patients with chronic neutropenia (CN) was presented at the 2023 |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to present additional CN Phase 2 clinical trial data in 1H 2024 BOSTON, Dec. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the presentation of additional preliminary data from its ongoing P |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on November 30, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an emplo |
XFOR: Mavorixafor NDA Accepted by FDA; PDUFA Date of April 30, 2024By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update NDA Accepted for Priority Review; PDUFA Action Date of April 30, 2024 On October 31, 2023, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for mavorixafor for the treatment of patients 12 and older |
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call TranscriptX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript November 9, 2023 X4 Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.15. Operator: Greetings and welcome to X4 Pharmaceuticals’ Third Quarter Financial and Operating Results Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder, […] |
X4 Pharmaceuticals to Participate in Upcoming November Investor ConferencesBOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being held in New York City, from November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference being held in New York City, from November 28-30, 2023. Stifel Healthcare ConferenceDate: Tuesday, Novemb |
Q3 2023 X4 Pharmaceuticals Inc Earnings CallQ3 2023 X4 Pharmaceuticals Inc Earnings Call |
X4 Pharmaceuticals Inc (XFOR) Reports Q3 2023 Financial Results and Corporate ProgressKey Developments Include FDA Priority Review for WHIM Syndrome Treatment |
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate UpdatesU.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if approved Presentations of additional data from ongoing Phase 2 clinical trial of mavorixafor in chronic neutropenia expected in 4Q 2023 and 1H 2024 Pivotal, global Phase 3 trial of mavorixafor in chronic neutropenia expected to initiate in 1H 2024 Conference call to be hosted today at 8:30 a.m. ET BOS |